Recent Updates
Recently added Catalysts

Chronic Lymphocytic Leukemia: 4 biotech companies with clinical-stage programmes

OncologyConcentrated betData as of 2026-09-04

Competitors4in the clinic
Median market cap$2.1Buniverse median $1.20B
Allocated capital$3.7B$13.1B competing
Phase 3 or filed12 mid, 1 early
Pure plays0this indication only
Capital rank49/299crowding rank 48

Chronic Lymphocytic Leukemia is a concentrated bet: only 4 US-listed developers are in the clinic, and the median one is worth $2.1B against a $1.20B universe median.

Scarcity is doing the work in that number. A thin field means an approval is shared with fewer rivals, and the market pays a premium for that position.

TGTX carries 66% of the $13.1B competing here, more than the other 3 companies combined.

$3.7B of allocated capital sits in Chronic Lymphocytic Leukemia, ranking it 49th of 299 indications by the money committed to it.

Companies developing drugs for Chronic Lymphocytic Leukemia 4

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
AAPGAscentage Pharma Group International UnsponsoredLisaftoclaxPhase 311$1.6BNo9No dated event
TGTXTG TherapeuticsUblituximabPhase 21$8.7BNo4 31 Dec 2026
NRIXNurix TherapeuticsNX-5948Phase 23$2.6BNo2No dated event
ADCTADC TherapeuticsLoncastuximab Tesirine and AcalabrutinibPhase 11$168MNo5 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. TGTX holds 66% of the $13.1B competing in this indication.

Why Chronic Lymphocytic Leukemia is a concentrated bet

Few competitors, each one large. The market pays a scarcity premium to compete here.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Chronic Lymphocytic Leukemia has 4 competitors and a median of $2.1B.

Oncology

Oncology holds $187B of the map's capital, 27.8% of the total, spread across 119 indications and 103 companies. 34 of those indications have more than one company competing.

See every Oncology indication on the map

Related indications in Oncology

Gastric Cancer8 companies · $3.6B · median $575MKnife fightRenal Cell Carcinoma5 companies · $3.4B · median $3.8BConcentrated betHER2 Positive Breast Cancer2 companies · $3.3B · median $10.2BConcentrated betBladder Cancer with FGFR3 Mutation1 company · $3.3B · median $6.6BUncontestedGlioblastoma6 companies · $3.0B · median $432MKnife fightWell-differentiated Non-functional Neuroendocrine Tumor1 company · $4.5B · median $9.0BUncontestedMetastatic Castration Resistant Prostate Cancer3 companies · $2.8B · median $4.0BConcentrated betBiliary Tract Cancer4 companies · $4.6B · median $7.4BConcentrated bet

Chronic Lymphocytic Leukemia pipeline questions

Which biotech companies are developing drugs for Chronic Lymphocytic Leukemia?

Ascentage Pharma Group International Unsponsored (AAPG, Lisaftoclax, Phase 3); TG Therapeutics (TGTX, Ublituximab, Phase 2); Nurix Therapeutics (NRIX, NX-5948, Phase 2); ADC Therapeutics (ADCT, Loncastuximab Tesirine and Acalabrutinib, Phase 1). Those are the 4 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Chronic Lymphocytic Leukemia.

How advanced is the Chronic Lymphocytic Leukemia pipeline?

Of the 4 clinical-stage programmes in Chronic Lymphocytic Leukemia, 1 is in Phase 3 or filed, 2 are in mid-stage development and 1 is in early-stage development.

Which company leads the Chronic Lymphocytic Leukemia field?

TGTX is the largest developer in Chronic Lymphocytic Leukemia, holding 66% of the $13.1B of market capitalisation competing in the indication. The median competitor is worth $2.1B.

When is the next Chronic Lymphocytic Leukemia catalyst?

The next dated catalyst in Chronic Lymphocytic Leukemia is TGTX on 31 Dec 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map